Helicobacter Pylori Infections - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 66 Pages - SKU: GMD6775931
|
|
Helicobacter Pylori Infections - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H1 2012', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections. 'Helicobacter Pylori Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Helicobacter Pylori Infections.
- A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Helicobacter Pylori Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Helicobacter Pylori Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Helicobacter Pylori Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Helicobacter Pylori Infections
- Helicobacter Pylori Infections Therapeutics under Development by Companies
- Helicobacter Pylori Infections Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Helicobacter Pylori Infections Therapeutics - Products under Development by Companies
- Helicobacter Pylori Infections Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Helicobacter Pylori Infections Therapeutics Development
- Affinium Pharmaceuticals, Inc.
- Deva Holding A.S.
- EastPharma Ltd.
- MerLion Pharmaceuticals Pte Ltd
- EpiVax, Inc.
- Vecta Ltd.
- Helicobacter Pylori Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- AVEC - Drug Profile
- Rifalazil - Drug Profile
- H.Pylori Vaccine - Drug Profile
- Lansoprazole + Amoxicillin + Clarithromycin + Metronidazole - Drug Profile
- GT08 - Drug Profile
- Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile
- Finafloxacin Oral - Drug Profile
- NCA 600 mg - Drug Profile
- Amoxicillin + Metronidazole + Omeprazole + Bismuth + Protexin Protect - Drug Profile
- Nigella Sativa Seeds + Omeprazole - Drug Profile
- Clarithromycin + Amoxicillin + Omeprazole - Drug Profile
- Omeprazole + Amoxicillin + Azithromycin - Drug Profile
- Omeprazole+ Amoxycilin + Clarithromycin - Drug Profile
- Metronidazole + Amoxicillin + Bismuth + Omeprazole - Drug Profile
- Sitafloxacin - Drug Profile
- RHB 105 - Drug Profile
- Fabl Inhibitor Program - Drug Profile
- Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile
- Helicobacter Pylori Infections Therapeutics - Drug Profile Updates
- Helicobacter Pylori Infections Therapeutics - Dormant Products
- Helicobacter Pylori Infections - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Helicobacter Pylori Infections, H1 2012
- Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Affinium Pharmaceuticals, Inc., H1 2012
- Deva Holding A.S., H1 2012
- EastPharma Ltd., H1 2012
- MerLion Pharmaceuticals Pte Ltd, H1 2012
- EpiVax, Inc., H1 2012
- Vecta Ltd., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Helicobacter Pylori Infections Therapeutics - Drug Profile Updates
- Helicobacter Pylori Infections Therapeutics - Dormant Products
- Helicobacter Pylori Infections Therapeutics - Dormant Products (Contd..1)
- List of Figures
- Number of Products under Development for Helicobacter Pylori Infections, H1 2012
- Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Gastrointestinal Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
